clinical research assistant internships

Clinical Research Assistant Intern

Medidata: Power Smarter Treatments and Healthier People

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,900+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company, is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @medidata .

The Program:

At Medidata, interns will have the opportunity to accelerate their careers by working closely with experienced professionals and gain valuable, hands-on, full-time work experience.  By being a part of our global organization, interns have the opportunity to work alongside our talented and committed professionals helping them to build a strong foundation for achieving their career goals.  For 12 weeks, beginning May 20, 2024, interns will have an opportunity to gain a deep understanding of what it means to be a Medidatian. United around a single goal of empowering smarter treatments and healthier people.  Medidatians work in a culture of curiosity, innovation and fun.  You will be contributing to the line of business with sustainable and meaningful work.

Our Summer Internship program also includes instructor led training, guided mentorship, exposure to senior leadership and community service.  In addition to individual and specific related responsibilities, each intern will participate in our Intern Innovation Lab.  Assigned to cross-functional teams, interns will work closely to develop an innovative solution to a business problem currently facing Medidata.  As they work diligently to present their final solutions to a panel of top Medidata leaders, we are confident that our interns will make a significant impact on our business.

The Position: 

We are looking for a research assistant to support clinical epidemiology projects. These projects include secondary analysis of clinical trial data from existing Medidata research archives and have a clear clinical focus and result in an abstract submission to a scientific meeting. The intern will provide support in this endeavor in several broad ways including through literature review, secondary data coding, statistical analyses, and scientific writing. They will be a key and very welcomed part of a vibrant, gracious, and highly successful scientific team.

Your Competencies:

• Good communication - verbal and written
• Detail-oriented, well organized, and an ability to prioritize work
• An interest in life sciences and the technology sector
• Experience with medical/scientific literature reviews
• Ability to manipulate data using conventional software
• Analytics experience, especially biostatistics, is a plus  (e.g., SAS, R)

Requirements: 

• Minimum education level required: Pursuing a Bachelor's  or Master’s degree.
• Fields of study: Public Health, STEM, pre-medical student
• Minimum years of experience: Completed Freshman year of college

As with all roles, Medidata sets ranges based on a number of factors including function, level, candidate expertise and experience, and geographic location. The salary range for positions that will be physically based in Cincinnati, Ohio is $32.00 to $37.00 per hour with a $3,500 sign on bonus.

Diversity statement

Equal opportunity.

MEDIDATA generates the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.

Clinical Research Assistant Intern

Internship, Research & Development

United States - MA, Boston

Requisition ID

Medidata: Power Smarter Treatments and Healthier People

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,900+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company, is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @medidata .

The Program:

At Medidata, interns will have the opportunity to accelerate their careers by working closely with experienced professionals and gain valuable, hands-on, full-time work experience.  By being a part of our global organization, interns have the opportunity to work alongside our talented and committed professionals helping them to build a strong foundation for achieving their career goals.  For 12 weeks, beginning May 20, 2024, interns will have an opportunity to gain a deep understanding of what it means to be a Medidatian. United around a single goal of empowering smarter treatments and healthier people.  Medidatians work in a culture of curiosity, innovation and fun.  You will be contributing to the line of business with sustainable and meaningful work.

Our Summer Internship program also includes instructor led training, guided mentorship, exposure to senior leadership and community service.  In addition to individual and specific related responsibilities, each intern will participate in our Intern Innovation Lab.  Assigned to cross-functional teams, interns will work closely to develop an innovative solution to a business problem currently facing Medidata.  As they work diligently to present their final solutions to a panel of top Medidata leaders, we are confident that our interns will make a significant impact on our business.

The Position: 

We are looking for a research assistant to support clinical epidemiology projects. These projects include secondary analysis of clinical trial data from existing Medidata research archives and have a clear clinical focus and result in an abstract submission to a scientific meeting. The intern will provide support in this endeavor in several broad ways including through literature review, secondary data coding, statistical analyses, and scientific writing. They will be a key and very welcomed part of a vibrant, gracious, and highly successful scientific team.

Your Competencies:

• Good communication - verbal and written
• Detail-oriented, well organized, and an ability to prioritize work
• An interest in life sciences and the technology sector
• Experience with medical/scientific literature reviews
• Ability to manipulate data using conventional software
• Analytics experience, especially biostatistics, is a plus  (e.g., SAS, R)

Requirements: 

• Minimum education level required: Pursuing a Bachelor's  or Master’s degree.
• Fields of study: Public Health, STEM, pre-medical student
• Minimum years of experience: Completed Freshman year of college

As with all roles, Medidata sets ranges based on a number of factors including function, level, candidate expertise and experience, and geographic location. The salary range for positions that will be physically based in Cincinnati, Ohio is $32.00 to $37.00 per hour with a $3,500 sign on bonus.

You decide what cookies Medidata will use

What are cookies.

Necessary cookies are essential and are used to provide you with services available through Medidata website. For instance, these cookies allow Medidata to remember your choices about cookies preferences, to record your interface customization trackers e.g. for the choice of language used by the website. Necessary cookies are enabled by default and cannot be switched off. To see the list of the cookies used for this purpose, click here .

Functional cookies are used to provide you with contents and proposals that correspond to your interactions. They may consist of information logged on your device or recorded as you navigate through Medidata website. These cookies also allow us to analyze site usage so we can measure and improve performance. To see the list of the cookies used for these purposes, click here .

Advertising cookies are used to enable Medidata and its trusted Medidata business stakeholders to serve ads that are relevant to your interests. The intention is to display ads that are relevant to you.

• Microsoft Clarity
• Microsoft Bing
• Oracle / Eloqua

To see the list of the cookies used for this purpose, click here .

Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms

• Advanced Search
• See Studies by Topic
• See Studies on Map
• How to Search
• How to Use Search Results
• How to Find Results of Studies
• How to Read a Study Record

• Learn About Studies
• Other Sites About Studies
• Glossary of Common Site Terms

• Submit Studies to ClinicalTrials.gov PRS
• Why Should I Register and Submit Results?
• FDAAA 801 and the Final Rule
• How to Apply for a PRS Account
• How to Register Your Study
• How to Edit Your Study Record
• How to Submit Your Results
• Frequently Asked Questions
• Support Materials
• Training Materials

• Selected Publications
• Clinical Alerts and Advisories
• Trends, Charts, and Maps
• Downloading Content for Analysis

• ClinicalTrials.gov Background
• About the Results Database
• History, Policies, and Laws
• ClinicalTrials.gov Modernization
• Media/Press Resources
• Linking to This Site
• Terms and Conditions
• Search Results
• Study Record Detail

An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older

• Study Details
• Tabular View
• No Results Posted

Inclusion Criteria:

Volunteers must meet the following inclusion criteria:

Type of participants

• Healthy volunteers or volunteers with a history of stable diseases that do not meet any of the criteria for non-inclusion in the study.

Other inclusion criteria

• Written informed consent of volunteers to participate in a clinical trial
• Volunteers who are able to fulfill the Protocol requirements (i.e., fill out a self-observation Diary, come to control visits).

Exclusion Criteria:

SARS-CoV-2 infection • A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.

Diseases or medical conditions

• Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
• Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.).
• Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
• The axillary temperature at the time of vaccination is more than 37.0 ° C.
• Acute infectious diseases (recovery earlier than 4 weeks before vaccination) according to anamnesis.
• Donation of blood or plasma (in the amount of 450 ml or more) less than 2 months before inclusion in the study.
• Severe and/or uncontrolled diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, gastrointestinal tract, liver, kidneys, hematopoietic, immune systems.
• Is registered at the dispensary for tuberculosis, leukemia, oncological diseases, autoimmune diseases.
• Any confirmed or suspected immunosuppressive or immunodeficiency condition in the anamnesis.
• Splenectomy in the anamnesis.
• Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l) according to anamnesis.
• Anorexia according to anamnesis.

Prior or concomitant therapy

• Vaccination with any vaccine carried out within 30 days before vaccination / the first dose of the studied vaccine or planned administration within 30 days after vaccination / the last dose of the studied vaccine.
• Prior vaccination with an experimental or registered vaccine that may affect the interpretation of the study data (any coronavirus or SARS vaccines).
• Long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs (immunoregulatory peptides, cytokines, interferons, immune system effector proteins (immunoglobulins), interferon inducers (cycloferon) during the six months preceding the study, according to anamnesis.
• Treatment with systemic glucocorticosteroids (≥ 20 mg of prednisone, or an analog, for more than 15 days during the last month).
• Volunteers who received immunoglobulin preparations or blood transfusion during the last 3 months prior to the start of the study according to anamnesis.

Other non-inclusion criteria

• Participation in any other clinical trial within the last 3 months.

Exclusion criteria:

• Withdrawal of Informed consent by a volunteer;
• The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;
• Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;
• Taking unauthorized medications (see section 6.2);
• The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;
• For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the Protocol that may affect the results of the study.
• For Patients and Families
• For Researchers
• For Study Record Managers
• Customer Support
• Accessibility
• Viewers and Players
• Freedom of Information Act
• HHS Vulnerability Disclosure
• U.S. National Library of Medicine
• U.S. National Institutes of Health
• U.S. Department of Health and Human Services

• Clinical Physics
• Translational Physics
• Proton Engineers
• Physics Residents
• Information Technology
• Past Members

Certification

Therapeutic Physics, American Board of Radiology

AAPM Jack Fowler Junior Investigators Award, 2004

Publications in Radiation Oncology and Medical Physics

Yan S, Lu HM, Flanz J, Adams J, Trofimov A, Bortfeld T. Reassessment of the necessity of the proton gantry:  analysis of beam orientations from 4332 treatments at the F.H. Burr proton center over the past 10 years. International Journal of Radiation Oncology Biology Physics 2016

Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. A prospective comparison of the effects of interfractional variations on proton therapy and IMRT for prostate cancer. International Journal of Radiation Oncology Biology Physics 2016

Patel AV, Lane AM, Morrison MA, Trofimov AV, Shih HA, Gragoudas ES, Kim IK. Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas Involving the Fovea. Ophthalmology 2015 

M oteabbed M, Sharp GC, Wang Y, Trofimov A, Efstathiou JA, Lu HM. Validation of a deformable image registration technique for cone beam CT-based dose verification. Medical Physics 2015;42:196-205

Cheney MD, Chen YL, Lim R, Winrich BK, Grosu AL, Trofimov AV, Depauw N, Shih HA, Schwab JH, Hornicek FJ, DeLaney TF. 18F-FMISO PET/CT visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine. International Journal of Radiation Oncology Biology Physics 2014

Safai S, Trofimov A, Adams JA, Engelsman M, Bortfeld T. The rationale for intensity-modulated proton therapy in geometrically challenging cases. Physics in Medicine and Biology 2013;58:6337-6353.

Giantsoudi D, Grassberger C, Craft D, Niemierko A, Trofimov A, Paganetti H. Linear energy transfer (LET)-Guided Optimization in intensity modulated proton therapy (IMPT): feasibility study and clinical potential. International Journal of Radiation Oncology Biology Physics 2013;87:216-222.

Wang. Y, Efstathiou JE, Lu H, Sharp GC, Trofimov A. Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to inter-fractional motion. Medical Physics 2013;40:071714

Zeng C, Giantsoudi D, Grassberger C, Goldberg S, Niemierko A, Paganetti H, Efstathiou JA, Trofimov A.  Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions. Medical Physics 2013;40:051708.

De Amorim Bernstein K, Sethi R, Trofimov A, Zeng C, Fullerton B, Yeap BY, Ebb D, Tarbell NJ, Yock TI, Macdonald SM. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. International Journal of Radiation Oncology Biology Physics 2013;86:114-20.

Trofimov A, Unkelbach J, DeLaney TF, Bortfeld T. Visualization of a variety of possible dosimetric outcomes in radiation therapy using dose-volume histogram bands. Practical Radiation Oncology 2012;2:164-171. 

Chen W, Unkelbach J, Trofimov A, Madden T, Kooy H, Bortfeld T, Craft D. Including robustness in multi-criteria optimization for intensity-modulated proton therapy. Physics in Medicine and Biology 2012;57:591-608.

Wang Y, Efstathiou J, Sharp G, Lu HM, Ciernik IF, Trofimov A. Evaluation of the dosimetric impact of inter-fractional anatomical variations on prostate proton therapy using daily in-room CT images. Medical Physics 2011

Grassberger C, Trofimov A, Lomax A, Paganetti H. Variations in linear energy transfer within clinical proton therapy fields and the potential for biological treatment planning. International Journal of Radiation Oncology Biology Physics 2011

Trofimov A, NguyenPL, EfstathiouJA, Wang Y, LuHM, EngelsmanM, MerrickS, ChengCW, WongJR, ZietmanAL. Interfractional variations in the set-up of pelvic bony anatomy and soft tissue, and their implication on the delivery of proton therapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 2011; 80:928-937.

Ding A, Gu J, Trofimov A, Xu XG.  Monte Carlo calculation of imaging doses from diagnostic multi-detector CT and kilovoltage cone-beam CT as part of prostate cancer treatment plans. Medical Physics 2010; 37:6199-6204.

MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D, Tarbell NJ, Yock T. Proton Radiotherapy for Pediatric Central Nervous System Germ Cell Tumors: Early Clinical Outcomes. International Journal of Radiation Oncology Biology Physics 2011; 79:121-129

Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal Dose-Volume Histogram Parameters Are Associated with Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial. International Journal of Radiation Oncology Biology Physics 2010; 78:1081-5

Suit H, Delaney T, Goldberg S, Paganetti H, Clasie B, Gerweck L, Niemierko A, Hall E, Flanz J, Hallman J, Trofimov A. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiotherapy and Oncology 2010; 95:3-22.

Kooy HM, Clasie BM, Lu HM, Madden TM, Bentefour H, Depauw N, Adams JA, Trofimov AV, Demaret D, Delaney TF, Flanz JB. A case study in proton pencil-beam scanning delivery. International Journal of Radiation Oncology Biology Physics. 2010; 76:624-30.

Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009; 15:312-8.

Seco J, Robinson D, Trofimov A, Paganetti H. Breathing interplay effects during proton beam scanning: simulation and statistical analysis. Physics in Medicine and Biology 2009; 54:N283-294.

Vrancic C, Trofimov A, Chan TCY, Sharp G, Bortfeld T. Experimental evaluation of a robust optimization method for IMRT of moving targets. Physics in Medicine and Biology 2009; 54: 2901-2914.

Bortfeld T, Chan TCY, Trofimov A, Tsitsiklis JN. Robust management of motion uncertainty in intensity-modulated radiation therapy. Operations Research 2008; 56:1461-1473

Nguyen PL, Trofimov A, Zietman AL. Proton beam or intensity-modulated therapy in the treatment of prostate cancer? Oncology 2008; 22:748-754.

Trofimov A, Vrancic C, Chan TCY, Sharp GC, Bortfeld T. Tumor trailing startegy for intensity-modulated radiation therapy of moving targets. Medical Physics 2008; 35:1718-1733

MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, Bortfeld T, Tarbell NJ, Yock T. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. International Journal of Radiation Oncology Biology Physics 2008; 71:979-987

Suit H, Kooy H,Trofimov A, Farr J, Munzenrider J, DeLaney T, Loeffler J, Clasie B, Safai S, Paganetti H. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiotherapy and Oncology 2008; 86:148-153.

Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, DeLaney TF, Shipley WU. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparsion. International Journal of Radiation Oncology Biology Physics 2007; 69:444-453 (follow-up: Letter to the Editor. In reply to Ms.Albertini et al. International Journal of Radiation Oncology Biology Physics 2007; 69:1334-1335)

Sharp GC, Lu HM, Trofimov A, Tang X, Jiang SB, Turcotte J, Gierga DP, Chen GTY, Hong TS. Assessing residual motion for gated proton-beam radiotherapy.Journal of Radiation Research 2007; 48:A55-59.

Censor Y, Bortfeld T, Martin B, Trofimov A. A unified approach for inversion problems in intensity-modulated radiation therapy. Physics in Medicine and Biology 2006; 51:2353-65.

Trofimov A, Rietzel E, Lu H, Martin B, Jiang S, Chen G, Bortfeld T. Temporo-spatial IMRT optimization: Concepts, implementation and initial results. Physics in Medicine and Biology 2005; 50:2779-98.

Paganetti H, Jiang H, Trofimov A. 4D Monte Carlo simulation of proton beam scanning: modeling of variations in time and space to study the interplay between scanning pattern and time-dependent patient geometry. Physics in Medicine and Biology 2005; 50:983-90.

DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005; 12:27-35

Weber DC, Trofimov AV, Delaney TF, Bortfeld T. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. International Journal of Radiation Oncology Biology Physics 2004; 58:1596-606.

Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, Chen GTY, Bortfeld T, Rosenthal S, Loeffler J, DeLaney T. Protons to Replace Photon Beams in Radical Dose Treatments. Acta Oncologica 2003; 42:800-8.

Trofimov A, Bortfeld T. Optimization of beam parameters and treatment planning for intensity modulated proton therapy. Technology in Cancer Research and Treatment 2003; 2:437-44.

Trofimov A, Bortfeld T. Beam delivery sequencing for intensity modulated proton therapy. Physics in Medicine and Biology 2003; 48:1321-31.

Publications in High-Energy Physics (with g-2 Collaboration, Brookhaven National Laboratory)

Bennett GW, et al. Improved limit on the muon electric dipole moment. Physical Review D 2009; 80:052008.

Bennett GW et al. Search for Lorentz and CPT violation effects in muon spin precession. Physical Review Letters 2008; 100:091602.

Bennett GW et al Statistical equations and methods applied to the precision muon (g-2) experiment at BNL. Nuclear Instruments and Methods in Physics Research A 2007; 579:1096-1116.

Bennett GW et al. Final report of the E821 muon anomalous magnetic moment measurement at BNL. Physical Review D 2006; 73:072003.

Bennett GW et al. Measurement of the negative muon anomalous moment to 0.7 ppm. Physical Review Letters 2004; 92:161802.

Bennett GW et al. Measurement of the positive muon anomalous moment to 0.7 ppm. Physical Review Letters 2002; 89:101804.

Brown HN et al. Precise measurement of the positive muon anomalous magnetic moment. Physical Review Letters 2001; 86:2227-31.

Sedykh SA et al. Electromagnetic calorimeters for the BNL muon (g-2) experiment. Nuclear Instruments and Methods A 2000; 455:346-60.

Brown HN et al. Improved measurement of the positive muon anomalous magnetic moment. Physical Review D 2000; 62:091101.

Carey RM et al. New measurement of the anomalous magnetic moment of the positive muon. Physical Review Letters 1999; 82:1632-35.